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Abstract
Clinical trials are the basis of Evidence-Based Medicine. Trial results are reviewed by experts and consensus panels for producing
meta-analyses and clinical practice guidelines. However, reviewing these results is a long and tedious task, hence the meta-analyses
and guidelines are not updated each time a new trial is published. Moreover, the independence of experts may be difficult to appraise.
On the contrary, in many other domains, including medical risk analysis, the advent of data science, big data and visual analytics
allowed moving from expert-based to fact-based knowledge. Since 12 years, many trial results are publicly available online in trial
registries. Nevertheless, data science methods have not yet been applied widely to trial data.
In this paper, we present a platform for analyzing the safety events reported during clinical trials and published in trial registries. This
platform is based on an ontological model including 582 trials on pain treatments, and uses semantic web technologies for querying
this dataset at various levels of granularity. It also relies on a 26-dimensional flower glyph for the visualization of the Adverse Drug
Events (ADE) rates in 13 categories and 2 levels of seriousness. We illustrate the interest of this platform through several use cases
and we were able to find back conclusions that are known in the literature. The platform was presented to four experts in drug safety,
and is publicly available online, with the ontology of pain treatment ADE.
Keywords: Data mining, Semantic web technologies, Ontology, Visual analytics, Information visualization, Glyph, Drug safety,
Adverse drug events, Pain treatments, Painkillers
1. Introduction
Clinical trials are the basis of Evidence-Based Medicine
(EBM) [1]. In particular, they provide evidence of the efficacy
and the safety of drug treatments. Trial results are reviewed by
medical experts and consensus panels during the process of per-
forming meta-analyses and writing clinical practice guidelines.
These processes remain widely manual and based on human ex-
pertise.
However, reviewing trial results is a tedious task, and the in-
dependence of experts is somehow questionable [2], e.g. it has
been shown that up to 90% of guidelines authors have ties to
drug firms [3]. Independent experts are rare: to be an expert,
one has to work on industry-funded trials, and disclosing links
of interests does not necessarily prevent biases [4]. Beyond in-
dependence, human expertise is not reproducible [5], leading to
variability in the recommendations across countries and organi-
zations [3]. Finally, the analysis of trial data relies heavily on
statistical methods that have known limits [6, 7], e.g. a signifi-
cant difference may actually be very small.
For example, a recent meta-analysis on tapentadol, a new opi-
oid drug for acute pain, included 8 randomized clinical trials and
3,706 patients, and showed that tapentadol was associated with
fewer gastrointestinal adverse drug events (ADE) [8]. However,
such a meta-analysis requires months of tedious expert work [9],
and is not updated each time a new trial is published. More-
over, clinicians might have difficulties to assess the quality of the
study and the independence of the authors, despite two investiga-
tors were involved in the process. Indeed, lack of confidence and
trust, and lack of time to appraise evidence have been identified
as barriers to the use of EBM by GPs [10].
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In many domains, the advent of data science, big data and vi-
sual analytics allowed moving from expert-based to fact-based
knowledge [11]. These methods have been shown to be efficient
for the analysis of medical risk [7]. Today, regarding clinical tri-
als, a lot of data is publicly available. Trial registration is manda-
tory since 2005 (International Committee of Medical Journal Ed-
itors) and 2008 (revised Declaration of Helsinki). Moreover, the
publication of most trial results is mandatory in the US since
2017 (FDAAA 801, Final Rule). In may 2020, more than 42,000
study results are available in ClinicalTrials.gov, the largest trial
registry. Nevertheless, methods from the field of data science
have not yet been widely applied to clinical trial data. In previous
studies, we showed that semantic web technologies and visual
analytics were an interesting option for accessing and comparing
drug knowledge [12] and for ranking and visualizing the proper-
ties of antibiotic agents [13, 14, 15]. Other authors also proposed
visual analytics for intelligent decision-making in medicine [16].
Similar methods could also be applied to trial result data found
in trial registries, and might complement the currently used sta-
tistical methods.
In the previous example on tapentadol, data science methods
may be used to easily and automatically produce rapid results on
ADE rates. A data mining platform may contain all ADE ob-
served during trials with publicly available results. A semantic
search engine may allow to automatically search for trials testing
tapentadol or other opioids for acute pain. Finally, the platform
may aggregate and compare the results of the retrieved trials,
showing within minutes that tapentadol has a lower risk of di-
gestive ADE. Of course, the generated evidence will still need to
be interpreted, and it would not have the strength of a full meta-
analysis. Nevertheless, such a platform could help experts while
performing meta-analyses, allowing to quickly test various hy-
potheses (e.g. what about comparing tapentadol to morphine?).
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In addition, it could also be used by non-expert clinicians for ver-
ifying the results of a published meta-analysis and assessing its
reproducibility, or for obtaining up-to-date results including the
latest studies.
The objective of this work is to design a web platform for the
semantic and visual mining of ADE observed in clinical trials
and published in trial registries, and to apply this platform to pain
treatments. This platform aims at helping experts and clinicians,
but also at illustrating what data science applied to trial public
data may bring to drug safety.
The rest of the paper is organized as follows. Section 2 de-
scribes related works on trial data and visualization. Section 3 de-
scribes the methods used for building the platform, including trial
selection, ontology modeling and population, ontology querying,
data correction and normalization, and visualization. Section 4
presents the resulting ontology of pain treatment ADE and the
proposed platform, and details several use cases and the com-
ments of experts in drug safety. Section 5 discusses the methods
and the results, and, finally, section 6 concludes with perspec-
tives.
2. Related works
2.1. Usage of clinical trial registries
Clinical trial data is available publicly in online registries, such
as ClinicalTrials.gov [17]. For some trials, it includes trial re-
sults, with the list of ADE observed in the various patient groups
of the study. Today, trial registries are used for systematic re-
views [18] and network meta-analyses [19, 20], comparing sev-
eral treatments by chaining trial results. But the efforts to stan-
dardize information from trials have not yet resulted in improve-
ments in the dissemination of trial evidence [9].
Similarly, in drug safety, many works focused on clinical data
collection from EHR and hospitals, but a recent review [21] high-
lighted that most of these works focused on extracting, repre-
senting and integrating information, rather than the use and the
dissemination of this information. For instance, C. Zhan et al.
applied computational methods to prescription data for detecting
ADE signals [22]. On the contrary, clinical trial data is mostly
analyzed with statistical methods, and few computational meth-
ods were proposed.
A few pioneering works focused on the direct use of trial data.
I. Atal et al. proposed a visual approach for viewing on a map-
ping the research effort and the health needs of low-income re-
gions [23]. J. Warner et al. proposed a network visualization of
chemotherapy treatment regimens [24]. Z. He et al. proposed
the use of text mining, bar charts and diagrams for the analysis
of clinical trial target populations [25]. Finally, J. Sjöbergh et al.
combined maps, parallel coordinates and diagrams for visualiz-
ing the individual patient data in a single trial [26].
Ontologies and semantic web technologies consist of formal
and unambiguous models; they have been widely applied to the
medical domain [27]. An ontology was proposed for structuring
clinical trial data, named OCRe [28]. However, this ontology is
very complex, and no tool exists for the automatic population of
the ontology from trial registries.
2.2. Multidimensional visualization techniques
Many techniques exist for the visualization of multidimen-
sional numeric data; in this section we will briefly review the
three main approaches. First, dimension reduction consists of re-
ducing the number of dimensions to 2 or 3, at the price of an
Figure 1: Examples of star glyphs (left) and flower glyphs (right). Dimension
axes are commonly omitted, especially in flower glyphs.
information loss. Then, the data can be visualized using a sim-
ple scatter plot. The main dimension reduction techniques are
Principal Component Analysis (PCA), Multidimensional Scaling
(MDS) [29], Self-Organizing Map (SOM) [30] and t-distributed
Stochastic Neighbor Embedding (t-SNE) [31]. Dimension reduc-
tion techniques are particularly useful for grouping similar items
in clusters. t-SNE is commonly used in bioinformatics, e.g. for
the visualization of transcriptomic [32], but in medicine, it was
also used for the classification of patients with Parkinson’s dis-
ease [33].
Second, parallel coordinates [34] consist of representing each
dimension by a parallel axis (usually vertical), and each data
point by a broken line that crosses each axis at the correspond-
ing value of the point in that dimension. Parallel coordinates are
often associated with interactive interfaces allowing the selection
of a subset of data points. They are particularly good at facili-
tating the discovery of patterns across the dimensions. Recently,
parallel coordinates were proposed for the study of exposure to
oxides of nitrogen and its relation to adverse birth outcomes [35].
Other applications include the visualization of multi-omics net-
works [36].
Third, glyphs consist of representing each data point by a small
icon called a glyph, and each dimension by a characteristic of
the glyph, e.g. the length or the color of a given element [37].
Two kinds of glyphs can be distinguished: metaphoric glyphs
that aim at looking like a common object, often related to the
data visualized but not necessarily, and abstract glyphs that are
geometric construction with no similarity to any common object.
An example of metaphoric glyph is Chernoff’s faces [38]: these
glyphs look like human faces. An example of abstract glyph is
the “stardinates” [39] or star glyphs [40] (see examples in Figure
1), which are similar to parallel coordinates but with the coordi-
nates organized in a star. Each dimension is represented by an
axis that crosses at the center, and each data point is represented
by a polygon. Contrary to parallel coordinates, each data point is
represented in a separate glyph. Flower glyphs [41, 42, 43, 44]
are close to star glyphs but follows a “flower” metaphor : each
glyph is a flower having one petal per dimension, the size of the
petal being proportional to the value of the data point in that di-
mension. An interest of flower glyphs is that they are less de-
pendent on the order in which the dimensions are displayed. In
Figure 1, glyphs A and B are the same but the order of the di-
mensions differs. Notice that A and B have the same inner area
with flower glyphs, but not with star glyphs.
Glyphs have shown their ability to visualize large datasets with
hundreds of dimensions [45]. In medicine, they have been used
for facilitating the analysis of semen [46], for example. Glyphs
are of particular interest for identifying similarity or differences
between data point.
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3. Materials and methods
3.1. Materials
Clinical trials were searched and extracted from ClinicalTri-
als.gov. We focused on pain, but we also considered fever, be-
cause of the large overlap between the two, both in terms of
symptoms (fever is often associated with pain) and drugs (e.g.
paracetamol and ibuprofen are both antipyretics and painkillers).
We used the following query: Condition (i.e. “pain” or “fever”)
+ Completed Studies + Studies With Results + Phase 3 or 4.
Searches were performed on the 18th January 2020.
From the resulting list of trials, we manually excluded: (1)
trials not involving the treatment of pain or fever (e.g. trial evalu-
ating the pain associated with the injection of a given vaccine, in
which pain is an outcome measure but not an indication, or trials
focused on insomnia caused by chronic low back pain), (2) trials
whose protocol does not allow comparing treatments (e.g. trials
comparing two care protocols where each patient in a group did
not receive the same treatment, or trials during which drug label-
ing errors occurred), (3) trials testing non-drug treatment (e.g.
behavioral training or surgery), (4) trials testing homeopathic
drugs, (5) trials where pain is treated by disorder-specific drugs
(e.g. chest pain caused by angina pectoris and treated by cardiac
drugs), and (6) trials testing anesthetic agents or painkillers used
during surgical operation. Trials comparing a drug treatment with
a non-drug treatment were included, but only the groups receiv-
ing drug treatments were considered in the present study.
3.2. Ontology modeling
We designed an ontology of pain treatment ADE in clinical
trials. Its purpose was not to fully model the domain of clinical
trials, as does OCRe for example. On the contrary, it aimed at be-
ing a simple model, limited to the needs of data mining of ADE,
and allowing us to handle ADE data as semantically linked data.
The use of the ontological formalism was motivated by the reuse
of existing tools designed for ontologies, and by the fact that on-
tologies are good at dealing with inheritance, i.e. various levels
of granularity. Here, we widely used inheritance in the model-
ing of indications (e.g. post-vaccination fever is more specific
than fever) and active principles (e.g. ibuprofen is more specific
than NSAI, Non-Steroid Anti-Inflamatory drugs). This will allow
querying the ontology at various levels of granularity.
In the ontology, the central class, Group, represents a group
of similar patients, receiving the same treatment(s) for the same
indication. ADE are observed in groups. On the contrary, indi-
vidual patients are not present in the ontology. ADE were clas-
sified in 2 levels of seriousness and 13 categories, including 12
anatomo-functional categories and 1 “Unclassified” category for
general symptoms (such as fatigue or unspecified infectious dis-
eases). These categories are more general than the 27 MedDRA
top-level System Organ Classes (SOC). A given ADE was al-
lowed to belong to more than one category, e.g. allergic rhinitis
belongs to both respiratory system and blood and immune sys-
tem.
We manually mapped the MedDRA terms to these 13 cate-
gories. Most MedDRA SOC could directly be mapped to a single
category (e.g. respiratory system). However, the “Investigations”
SOC required more work, in order to associate each abnormal
test result to the right category (e.g. “Tidal volume decreased”
was associated with the respiratory system category).
The resulting ontology was interfaced with Python scripts
using the Owlready 2 ontology-oriented programming module
[47, 48]. The ontology was stored in the Owlready 2 quadstore,
as an SQLite3 database.
3.3. Ontology population
The pain treatment ADE ontology was populated from Clini-
calTrials.org XML data, using a semi-automatic process. In Clin-
icalTrials.org, trials, groups and ADE observations are well struc-
tured, and ADE are classified according to the 27 System Organ
Class (SOC) of the MedDRA terminology, and in 2 classes of se-
riousness (serious vs non-serious). In most cases, the ADE label
corresponds to a MedDRA term. Consequently, we automatically
extracted and inserted these pieces of data in the ontology, using
Python scripts.
On the contrary, the treatments received by the patient groups
are not coded in ClinicalTrials.org, but only present in free-text
fields. Similarly, the precise indications of these treatments are
available only in free text; although MeSH (Medical Subject
Headings) terms are provided, they often remain too general (e.g.
pain without more precision). Thus, treatments and indications
cannot be extracted without a manual intervention.
We wrote Python scripts for extracting the free-text values,
and automatically recognizing named entities and dose regimens.
The output was formatted in CSV files (Comma-Separated Val-
ues). Then these files were opened in a spreadsheet software (Li-
breOffice Calc) and manually reviewed by a pharmacist working
in medical informatics (JBL). The entire process took about 1
month.
A first script aimed at automatically detecting the names of ac-
tive principles (using a list extracted from UMLS, Unified Med-
ical Language System), their dose, dose unit and number of in-
takes per day (using regular expressions targeting common ex-
pressions such as “bid” : bis in die, i.e. twice per day). A sec-
ond script aimed at automatically extracting indication, from trial
summary, description and MeSH terms. We measured the perfor-
mance of the two scripts, by comparing the data extracted auto-
matically by the scripts with the same data after correction during
the manual review.
When coding doses and numbers of intakes per day, we al-
lowed the use of a range with a minimum and a maximum value
(e.g. 5-10 mg or 1-2 intakes per day). In addition, when the dose
varied over time, we kept only the maintenance dose.
The active principles and indications identified were added
to the ontology, and hierarchically structured. Active principles
were classified according to three dimensions: chemical structure
(e.g. steroid), pharmacological activity (e.g. antihistamine) and
main indication (e.g. anti-epileptics). Indications were classi-
fied according to four dimensions: anatomy (e.g. musculoskele-
tal pain), etiology (e.g. neuropathic pain), chronicity (i.e. chronic
or acute pain) and severity (i.e. mild, moderate or severe pain).
These classifications were highly inspired by existing terminolo-
gies such as ATC (Anatomical Therapeutical Chemical classifica-
tion of drugs) or ICD10 (International Classification of Diseases,
release 10).
ADE terms were extracted from ClinicalTrials.gov and auto-
matically mapped to MedDRA terms using their textual English
label. When no corresponding MedDRA term was found, the
term was simply associated with the MedDRA SOC present in
ClinicalTrials.gov. While more general, the SOC still permits re-
lating the ADE to one of our 13 categories of ADE.
Several trials include a titration period, mainly for opioid
painkillers. A typical design study for comparing a given opioid
with a placebo is as follows: an open-label titration period with
the test drug, including all patients, then randomization followed
by a maintenance period with two groups, one taking the test drug
and the other taking a placebo. In this case, we chose to include
in the ontology the ADE observed during the titration period, but
3
without mixing them with those observed in the maintenance pe-
riod, because there is no titration period for placebo and thus no
comparison is possible.
The ontology population was performed by a pharmacist work-
ing in medical informatics (JBL), and took about 1 month.
3.4. Ontology querying
We designed a query procedure for searching the ontology.
The procedure takes as input one or more group definitions. Each
group definition may include criteria regarding the trial (e.g. re-
strict to randomized trials), the indication (e.g. restrict to cancer
pain) and the active principles (e.g. opioid or morphine). The
ontology allows the use of various levels of granularity in the
formulation of the query, as in the latter example. Several active
principles may be mentioned for a given group (corresponding to
a bi- or tritherapy), and, for each, a specific release (immediate
or modified), range of dose (e.g. 5-10 mg) and number of intakes
per day (e.g. 1-2 times per day) may be specified.
In addition, we considered two particular situations when
querying on active principles. First, we also allowed an “open
list” search, that returns groups with the active principles queried
possibly in association with others, e.g. morphine alone or as-
sociated with any other active principle. This “open list” search
comes in addition to the usual “closed list” search, which is the
default. Second, it is sometimes interesting to perform a compar-
ison between two treatments defined at different levels of granu-
larity, e.g. to compare tapentadol vs opioids. In this comparison,
“opioids” implicitly means “opioids other than tapentadol”, since
tapentadol is an opioid. Thus, we also supported exclusion in the
search process.
For a single query, the procedure returns three sets of results.
The first one, direct comparisons, includes only direct compar-
isons, i.e. trials in which all the groups queried are present. The
second one, direct and indirect comparisons, includes both direct
comparisons and indirect comparisons via placebo, i.e. trials in
which only some of the groups queried are present, and where a
placebo group is present for performing an indirect comparison
normalized by placebo (see next section). The third one, abso-
lute values, includes all trials containing at least one of the groups
queried, without any correction or normalization.
As a consequence, the first result set (direct comparisons) has
the fewest number of trials and patients but the highest data qual-
ity. On the contrary, the third result set (absolute values) has the
highest number of trials and patients but the lowest data quality.
The user may choose the desired result sets, e.g. one may use
the direct comparisons and defaults to the other result sets when
there are not enough patients.
3.5. Data correction and normalization
We implemented three data correction and normalization
methods. First, per-trial number of patients correction was im-
plemented for direct comparisons when more than one trial is
involved in the comparison. For example, let us consider two
trials T1 and T2, both comparing two drugs D1 and D2. T1 in-
cludes 100 patients treated with D1 and 100 patients treated with
D2, and T2 includes 100 patients treated with D1 but 200 patients
treated with D2. Without correction, a higher weight is given to
the group T2-D2, since patients are more numerous in this group.
This is a potential bias if T2 is at higher (or lower) risk of ADE,
e.g. because the trial involves post-vaccination fever and the vac-
cine may cause additional ADE. Consequently, we need to nor-
malize the data.
We propose to reduce the weight given to each group using a
correction factor, so as the weight given to each group is equiva-
lent to the weight of the smallest group in the same trial. In the
previous example, the correction factors will be 1.0 for groups
T1-D1, T1-D2 and T2-D1, but 0.5 for T2-D2. This gives an equiv-
alent weight to T2 for both D1 and D2. In the general case, for a
trial T with n group D1 to Dn, the correction factor for group Dx
is:
wx =
min(|TDi| f or i ∈ [1, n])
|TDx|
where |TDi| is the number of patients in the group with drug Di
in trial T .
When computing the correction factor wx, we used the mini-
mum group size and not the average, because using the average
would reduce the weight of the larger groups but also increase the
weight of the smaller groups. In case of very small groups, using
the average would give a disproportional importance to the rare
events occurring in these small groups (e.g. 1 stroke in a group
of 10 patients). On the contrary, using the minimum ensures that
no patient counts for “more than one”.
Second, placebo normalization was implemented for indirect
comparisons. In indirect comparisons, the number of ADE ob-
served needs to be adjusted according to the number of ADE ob-
served in placebo groups. For example, let us consider an indi-
rect comparison between two drugs D1 and D2, using two trials
T1 and T2. In T1, D1 is compared to placebo P, and, in T2, D2
is compared to P, each group including 100 patients. Let us con-
sider E, a given ADE, e.g. vomiting. We denote by E(TiD) the
number of occurrences of E in trial Ti in the group taking drug D.
Let E(T1D1) = 20, E(T1P) = 10, E(T2D2) = 30, E(T2P) = 30.
These numbers suggest that, despite more vomitings were ob-
served with D2 than D1, D2 is at lower risk of causing vomiting
because it caused as much vomitings as placebo, while D1 caused
more. In facts, the difference observed between D1 and D2 is par-
tially due to the difference in clinical conditions between T1 and
T2.
Here, the average rate of E in the placebo group is 10+30100+100 =
20%. But, in T1, the rate of E in the placebo group is 10100 = 10%,
thus there is another 10% missing. Adding these 10% to the rate
of E in the D1 leads to a corrected number of occurrences of
20 + 0.1 × 100 = 30. Similarly, for D2 in trial T2, the corrected
number of occurrences will be 30 − 0.1 × 100 = 20.
In the general case, the corrected number of occurrences of E
for the group TxDy is:
Ec(TxDy) = E(TxDy) +
(∑n
i=1 E(TiP)∑n
i=1 |TiP|
− E(TxP)|TxP|
)
× ∣∣∣TxDy∣∣∣
where n is the number of trials,
∑n
i=1 E(TiP)∑n
i=1 |TiP| is the average rate of
E in placebo over all trials, and E(TxP)|TxP| the average rate of E in
placebo in the considered trial Tx.
Third, when direct and indirect comparisons are mixed, we
need to ensure that the proportion of patients coming from di-
rect comparisons is the same in each of the compared groups.
Let us consider a mixed comparison between two drugs D1
and D2, including T1 (direct comparison) with E(T1D1) = 40,
|T1D1| = 100, E(T1D2) = 50, |T1D2| = 100, but also two indirect
comparisons: T2 with E(T2D1) = 10, |T2D1| = 100 and T3 with
E(T3D2) = 22, |T3D1| = 200 (after applying the placebo normal-
ization described above). Despite the fact that D1 is associated
with lower ADE rate than D2 in both direct (T1) and indirect (T2
vs T3) comparisons, the uncorrected mean ADE rate is higher for
D1 ( 40+10100+100 = 25%) than for D2 (
50+22
100+200 = 24%). Actually, it
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Figure 2: Structure of the flower glyph, with the 13 ADE categories.
gives a higher weight to T1 for D1, and T1 is associated with a
higher overall rate of ADE (possibly due to the trial conditions).
We correct the data as follows. We compute the overall indirect
/ direct patient ratio r. In the previous example, r = 100+200100+100 = 1.5.
Then, for each of the compared group D, we weighted the direct
comparisons with a factor kdir(D) and the indirect comparisons
with a factor kind(D) in order to obtain a ratio equal to r. Let
us note |D|dir and |D|ind the number of patients in the direct and
indirect comparisons for group D, respectively. We have:
kdir(D) = min
(
1,
|D|ind
|D|dir × r
)
kind(D) = min
(
1,
|D|dir × r
|D|ind
)
As previously, the weight given to a patient cannot be higher
than 1. In the previous example, we have kdir(D1) = 100100×1.5 =
0.667, kind(D1) = 1, kdir(D2) = 1 and kind(D2) = 100×1.5200 = 0.75.
3.6. Visual analytics
Let us consider a 26-dimensional numeric dataset, with 2 di-
mensions for each ADE category, one for all ADE in the category
and the other for serious ADE only. In this dataset, each group
of similar patients in the query corresponds to a data point. We
chose glyphs for the visualization of the dataset, because they
are particularly efficient for identifying differences between data
points. Moreover, dimension reduction techniques would imply
an important information loss (see section 2.2), and parallel co-
ordinates consider each dimension in the same way, while our 26
dimensions are organized in 13× 2 corresponding to the 13 ADE
categories and the 2 levels of seriousness.
We adapted flower glyphs for visualizing the per-category and
per-seriousness level rates of ADE observed in a group. Unclas-
sified ADE are represented by a white circle at the center of the
flower, and each of the 12 remnant categories is represented by
a colored petal. Both the position of the petal and its color were
chosen in order to facilitate the understanding and the memoriza-
tion of the category. For example, nervous system is at the top
and in gray (think of the brain and the “gray matter”), while the
urinary system is in yellow at the bottom. When no “obvious”
colors were available, arbitrary colors were used, e.g. green for
genital system and reproduction. Figure 2 shows the structure
of the flower glyph and the color and position of the 13 ADE
categories.
Contrary to what was found in the literature, we encoded the
ADE rate by the area of the petal, and not by its length. The
area of the center circle and the petals is thus proportional to the
observed rate of the corresponding ADE (including both serious
Figure 3: General model of the ontology of pain treatment ADE in UML. Re-
lations in black were extracted automatically, while manual intervention was re-
quired for those in red.
and non-serious ADE). When present, serious ADE were repre-
sented by a darker central circle or a darker smaller petal. The
area of this darker region is proportional to the observed rate of
serious ADE in the given category.
This flower glyph takes advantage of the ability of the human
vision to distinguish at least 12 directions, as in an analog clock,
and its higher sensitivity to area rather than to distance [49]. In
addition, compared to a bar chart, the overall triangular shape
of petals associated with area proportionality allows giving more
attention to small values, i.e. if the rate of ADE is multiplied by
2, the length of the petal is multiplied by less than 2, because
the area increases faster than the length. This acts similarly to a
logarithmic scale, although not logarithmic from a mathematical
point of view. Consequently, small values remain visible when
much higher values are present.
We added interactivity to flower glyphs, as follows. When the
mouse if over a region (the central circle or a petal), a popup
bubble displays the ADE category label and the associated rate of
ADE and serious ADE, with the most frequent ADE and serious
ADE in the category. When the mouse is clicked, the webpage is
scrolled down to display the entire list of ADE in this category.
Finally, when several glyphs are present, we added a ∆ (delta)
button. When this button is mouse-hovered, the outline of the
selected glyph is drawn as a wire frame over the other glyphs, in
order to facilitate comparison.
3.7. Implementation details
The search procedure was implemented with Owlready, which
translates the query into an SQL query. The visual analytics was
implemented in a web platform, using Python 3 with Flask and
Owlready, web technology (HTML, CSS) and Brython, a client-
side Python interpreter.
3.8. Use cases and expert opinions
Several use cases were designed for the platform. Most of
them were focused on trying to find back already known results,
e.g. from meta-analysis, in order to validate our approach. An ad-
ditional use case was designed by selecting an indication in the
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Figure 4: Selection of clinical trials for the study.
ontology and comparing the available drugs, in order to search
for possible new insights.
The proposed platform was presented to four experts in drug
safety, from the French drug agency (Agence Nationnale de Sécu-
rité du Médicament et des produits de santé, ANSM), using the
use cases. Then, the comments, opinions and suggestions of the
experts were collected during a focus group session.
4. Results
4.1. The ontology of pain treatment ADE
Figure 3 shows the general model of the pain treatment ADE
ontology, in UML (Unified Modeling Language). In this model,
Group is the central class and represents a group of similar pa-
tients, in terms of clinical conditions and treatments received. A
clinical trial contains one or more periods; most trials either in-
clude a single period or an open-label titration period followed
by a maintenance period. A few also include an open-label con-
tinuation or pick-up period. Each period includes one or more
comparable group. Each group has one or more drug treatments,
prescribed for one or more indications. ADE are observed in
groups, and are associated with a MedDRA term and a serious-
ness Boolean status. 18,090 ADE terms were extracted from
ClinicalTrials.gov. 17,304 (95.7%) were automatically mapped
to MedDRA terms using their label, the others being associated
with the MedDRA SOC present in ClinicalTrials.gov. ADE with
the same MedDRA term may differ in seriousness, e.g. diarrhea
might be serious for newborns but not for adults. Finally, each
MedDRA term is associated with one or two of the 13 ADE cat-
egories.
Figure 5: Histogram of the completion dates of the selected trials.
Inheritance is present at three levels: ClinicalTrial, Indication
and ActivePrinciple. Notice that OWL ontologies allow multi-
ple instantiation in addition to multiple inheritance, i.e. a given
clinical trial can belong to several classes, e.g. RandomizedClin-
icalTrial and InterventionalClinicalTrial. In Figure 3, relations
in red were extracted from ClinicalTrials.org semi-automatically,
with manual intervention, while those in black were extracted au-
tomatically.
Figure 4 shows the selection and exclusion of clinical trials
during the study. 582 clinical trials were included. In addition
to the criteria mentioned in section 3.1, one trial was excluded
because results data was not present in ClinicalTrials.gov (inves-
tigators lost data during flooding, NCT01401049), and two trials
because they contain only results related to efficacy. Figure 5
shows a histogram of the completion date of the selected trials.
Most trials were completed after 2007.
During the ontology population, 1,394 groups were extracted
with 1,653 individual drug treatments (a group may have sev-
eral treatments, e.g. 2 in case of a bitherapy). The Python script
extracted the right indication for 77.3% of the groups, the right
severity for 97.1%, and the right chronicity for 71.2%. It also ex-
tracted the right active principle for 77.7% of the individual drug
treatments, the right release for 90.1%, the right route for 70.3%,
the right dose for 55.3%, the right dose unit for 61.4%, and the
right number of intakes per day for 74.2%.
The resulting ontology includes 582 trials, 1,354 groups
and 157,665 patients, 201 active principle classes, 194 indi-
cation classes, and 148,843 reported individual ADE. It was
formalized in OWL 2.0 and saved in RDF/XML, and it con-
tains 299,341 RDF triples. The ontology is publicly available at
http://www.lesfleursdunormal.fr/static/appliweb/pain/pain_onto.zip.
4.2. The data mining web platform
The proposed platform is available online at
http://www.lesfleursdunormal.fr/appliweb/pain, and is fully
bilingual (English and French). It has been tested with both
Mozilla Firefox and Google Chrome. Figure 6 shows a screen-
shot of the search interface. The user can enter one or more
groups. Each group may contain one or several comma-separated
classes of trial, indication and active principle. Auto-completion
is used for facilitating the entry of trial types, indications and
active principles, and the entire hierarchies can be displayed
by clinking on the field labels. If several active principles are
entered for a given group, the per-drug fields (i.e. release, route,
daily dose, dose unit and intakes/day) are subdivided with one
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Figure 6: Screenshot of the search interface.
Figure 7: Screenshot of the results interface, with two flower glyphs and a bubble showing details on a petal.
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field for each active principle. In the results, each group will
be displayed in a separate flower glyph. In Figure 6, the user
defined two groups: “oral acetaminophen” and “oral ibuprofen”.
When entering active principles, the “etc” special label can be
used for defining an “open list” of active principles, e.g. “mor-
phine, etc” for any treatment that includes morphine (possibly
with other active principles). In addition, when a group’s active
principles are more general than a previous group, we automati-
cally exclude the results of the more specific group from the re-
sult of the more general group. For example, when comparing
tapentadol with opioids, the search will automatically consider
“opioids other than tapentadol” (labeled “other opioid” in the re-
sults, for brevity).
Figure 7 shows a screenshot of the results interface, after the
user performed the query shown in Figure 6. The results interface
includes three parts, organized vertically. First, the three tabs at
the top of the screen allows selecting the result sets: direct com-
parisons, direct and indirect comparisons, or absolute values. The
first one includes only trials with all searched groups, the second
one also includes trials with only some of the queried groups and
a placebo group allowing adjusting the ADE observed according
to the values observed for the placebo (as explained in section
3.5), and the third one includes all groups found independently
from the trial they belong to, without any corrections. The num-
ber of trials and patients increase from the left to the right tab,
but the quality of the data decreases. The “absolute values” re-
sult set is surely not sufficient for drawing conclusions; however,
it is very useful for confirming or invalidating the conclusions
observed in the other result sets, or for obtaining general trends
when the other result sets are not available.
Second, flower glyphs display the rates of the various cate-
gories of ADE, for each group. The user can mouse over the re-
gion of the glyph to obtain more detail in a popup bubble, or click
to scroll down to the entire list of ADE in the chosen category.
At the bottom right of the glyph, the ∆ button allows drawing
the outline of the select glyph on top of the other glyphs. This
permits fine comparison and facilitates the identification of small
differences. At the bottom of the flower glyphs, a line of text
summarizes the corrections that were applied to the data.
Notice the very high ADE rates shown in Figure 7: more than
200%, i.e. more than 2 ADE per patients on average. These
rates correspond to the number of events observed during tri-
als, but may not correspond to the real rate of ADE caused by
the drug in normal clinical use: of course, the ADE rate of ac-
etaminophen and ibuprofen is not 200%. In particular, the ADE
may be observed during a long period (several months or even
years, i.e. for acetaminophen and ibuprofen, some trials on post-
vaccination fever cover all vaccinations during childhood), and
the events observed may be due to the drug taken, but also to the
patient disorders or the conditions of the trial (e.g. ADE may be
caused by the vaccine in the previous example) and to random
hazards (e.g. an infection may occur during the trial, unrelated
to the treatment). However, the rates given by the platform are
comparable for the “direct” and “direct + indirect” result sets,
allowing the comparison of the various treatment options.
The size of the flower glyphs reduces when the number of
glyphs increases. Figure 8 shows a “bouquet” of flower glyphs
for the 8 most common pain treatments in the ontology. We can
observe that digestive ADE are the most frequent, followed by
neurologic ADE.
Third, a second set of tabs allows displaying various tabular
information. The tabs are: (1) “All events”: this tab displays the
entire list of all ADE, sorted by category and then by rate. Back-
Figure 8: Flower glyphs corresponding to the 8 most common pain treatments
in the ontology, using the “absolute values” result set. Hence the glyphs are not
comparable since the patient conditions may differ, but these glyphs give an idea
of the type of ADE one may expect which each drug when used in its own typical
conditions.
Figure 9: Example of typical search strategies in the platform.
ground reddish colors are used to represent frequencies visually,
from white (0%) to red (5% or more) on a logarithmic scale. (2)
“Serious events”: this tab is similar to the previous one, but dis-
plays only serious ADE. (3) “Indication summary”: this tab dis-
plays the indications of the selected trials, ordered by frequency.
Radio buttons allow selecting one of the indications, in order to
restrict the search to the chosen indication. (4) “Treatment sum-
mary”: this tab displays the list of treatments tested in the se-
lected trials, ordered by frequency. It is present only if no active
principles were entered in the query, e.g. the user may search for
“cancer pain” and will find in this tab the most frequently tested
treatments for cancer pain. Checkboxes allow selecting all or part
of these treatments, with a button for performing a new search
comparing the selected treatments in the previously entered in-
dication. (5) “Comparable treatments”: this tab displays similar
treatments used as comparators in trials, ordered by frequency.
It is present only if active principles were entered in the query.
For example, the user may search for “tramadol”, and will get in
this tab the list of treatments compared to tramadol. Checkboxes
allow selecting some comparable treatments, with a button for
adding the selected treatment into the current search. (6) “List
of trials”: this tab lists all the trials in the current result set, with
links to pages displaying the ADE observed in each trial. It also
displays the per-trial rate of ADE for each group, allowing the
identification of outlier trials. Finally, it includes checkboxes, al-
lowing the exclusion of some trials from the result set. Figure 9
shows several search strategies made possible using tabs 3-5.
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Figure 10: Flower glyphs comparing elagolix to placebo.
4.3. Use cases
4.3.1. Acetaminophen vs ibuprofen
Acetaminophen, ibuprofen and aspirin are the three main
OTC (Over The Counter, i.e. without medical prescriptions)
painkillers taken by patients. However, aspirin is no longer rec-
ommended for such use. Thus, we found no recent trial involv-
ing aspirin as a painkiller. Figure 7 shows the direct comparison
of oral acetaminophen vs oral ibuprofen, including 9 trials and
3,042 patients1. The results show slightly fewer ADE with ac-
etaminophen (203.1% vs 214.7%), as well as for serious ADE
(4.4% vs 4.9%). In particular, acetaminophen is associated with
fewer unclassified ADE (mostly fevers, 54% vs 70%). Neverthe-
less, the difference is low and probably not significant, and the
ADE profile of both drugs is very similar. These results are con-
sistent with a meta-analysis that concluded, 10 years ago, that
acetaminophen and ibuprofen are equally safe [50], but the re-
sults presented here include more recent trials.
Two main indications are present in the “Indication summary”
tab: post-vaccination fever in children and pain following dental
extraction. Interestingly, separate analyses (easily available using
the radio buttons in the tab) suggest that acetaminophen has fewer
ADE in the former indication and ibuprofen in the latter.
4.3.2. Elagolix
Elagolix is a gonadotropin-releasing hormone antagonist drug
approved in 2018 in US, for the treatment of pain associated with
endometriosis in women [51]. However, elagolix is known to be
associated with frequent ADE such as hot flushes [52].
After searching for elagolix alone, the “comparable treat-
ments” tab shows that elagolix was only compared with placebo,
during two trials. The tab’s checkbox permits the addition of
placebo to the query, leading to Figure 102. We can clearly
see that the ADE rate is higher for elagolix, especially for car-
diovascular and genital/reproductive ADE (corresponding to the
red and green petals). In particular, elagolix is associated with
34% risk of hot flush (classified in both cardiovascular and gen-
ital/reproductive ADE categories, and thus counting for half in
each) and a 5.6% risk of amenorrhea. For placebo, these risks
are 8.6% and 0.27%, respectively. These values can be easily ob-
tained in the petal popup bubbles. These results clearly illustrate
the high ADE rate with elagolix.
1Available online at http://www.lesfleursdunormal.fr/appliweb/pain?
group_1_ap=acetaminophen&group_1_route=oral&group_2_ap=ibuprofen
&group_2_route=oral
2Available online at http://www.lesfleursdunormal.fr/appliweb/pain?
group_1_ap=elagolix&group_2_ap=placebo
Figure 11: Flower glyphs comparing oral tapentadol to other oral opioids for
acute pain.
Figure 12: Flower glyphs comparing tramadol to other opioids.
4.3.3. Tapentadol
As said in the introduction, a recent meta-analysis showed that
tapentadol was associated with less digestive ADE than other opi-
oids when prescribed for acute pain [8]. Figure 11 shows the di-
rect comparison of oral tapentadol with other oral opioids3. Six
trials were found, involving 2,819 patients. On the flower glyphs,
we can clearly see the difference in digestive ADE (56% vs 86%).
Contrary to the meta-analysis, the other opioids involved in the
comparison are not limited to a single option, but include both
oxycodone and morphine, as shown in the “Treatment summary”
tab. One may perform additional searches to compare tapentadol
to oxycodone and morphine separately, showing that tapentadol
has fewer digestive ADE in each comparison.
4.3.4. Tramadol
Tramadol is an opioid painkiller used to treat moderate pain. It
is classified as a level-2 painkiller (out of 3 levels). Tramadol was
considered as having fewer risks of ADE compared with other
more powerful opioids. However, it appeared that tramadol was
involved in an important number of ADE, including serotoniner-
gic syndrome [53], vomiting and sleep disorders, and was at risks
of misuses and dependence. A recent study involving Egyptian
students showed that 12.3% of them were taking tramadol, and
that 30% of the tramadol-consumers had dependence [54]. An-
other study showed that patients receiving tramadol after surgery
had similar, or even higher, risks of prolonged opioid use com-
pared with patients receiving other opioids [55]. In France, the
French drug agency (Agence Nationale de Sécurité du Médica-
ment et des produits de santé, ANSM) recently published a com-
3Available online at http://www.lesfleursdunormal.fr/appliweb/pain?
group_1_indication=acute pain&group_1_ap=tapentadol&group_1_route=oral
&group_2_indication=acute pain&group_2_ap=opioid&group_2_route=oral
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Figure 13: ADE observed during the treatment of peripheral neuropathic pain,
and the treatment summary.
municate4, and reduced the maximum prescription duration for
tramadol, from 12 to 3 months.
Figure 12 shows the comparison of oral tramadol with other
oral opioids5. Here, no direct comparisons were found; this was
expected since tramadol is not considered as comparable with
level-3 opioids like morphine. The indirect comparison result
set, normalized by placebo, includes 29 trials (5 for tramadol and
24 for other opioids) and 8,851 patients. It clearly appears that
the ADE profile of tramadol is very similar to the one of other
oral opioids, with a high ADE rate and many digestive and ner-
vous ADE. This supports the facts that tramadol is potentially as
dangerous as other opioids.
On the contrary, when looking at the details of the psychologi-
cal ADE, no occurrences of drug abuse were found for tramadol.
But this may be due to the conditions of clinical trials, which
often have relatively short durations, and very controlled doses
and protocols that limit the risk of drug abuse. Moreover, certain
trials may exclude participants with a history of substance abuse.
4.3.5. Peripheral neuropathic pain and gabapentinoids
Peripheral neuropathic pain is a pain caused by damages to
peripheral nerves. Typical causes of damages are diabetic neu-
ropathy, postherpetic neuralgia and trauma. The 2010 guide-
lines on the pharmacological treatment of neuropathic pain [56]
from EFNS (European Federation of Neurological Societies)
recommends duloxetine, pregabalin, gabapentin, tricyclic an-
tidepressants or venlafaxine as first-line treatment for painful
polyneuropathy (including diabetic neuropathic pain) and pre-
gabalin, gabapentin, tricyclic antidepressants or lidocaine for
4“TRAMADOL : une mesure pour limiter le mésusage en France - Point
d’information”, 16/01/2020, https://www.ansm.sante.fr/S-informer/Points-d-
information-Points-d-information/TRAMADOL-une-mesure-pour-limiter-le-
mesusage-en-France-Point-d-information
5Available online at http://www.lesfleursdunormal.fr/appliweb/pain/?
group_1_ap=tramadol&group_1_route=oral&group_2_ap=opioid&group_2_route=oral
Figure 14: Indirect comparison of the four main treatments for peripheral neuro-
pathic pain.
post-herpetic neuralgia. In 2015, a systematic review and meta-
analysis recommended gabapentin, gabapentin enacarbil, prega-
balin, duloxetine, venlafaxine or tricyclic antidepressants as first-
line treatment for neuropathic pain in adults [57]. In 2013, a
meta-analysis concluded that gabapentin has the most favorable
balance between efficacy and safety for diabetic neuropathic pain
[20], but since this study did not analyze efficacy and safety sep-
arately, it is difficult to know whether this conclusion is due to
efficacy, safety or a mix of both.
Figure 13 shows the results obtained when searching for “pe-
ripheral neuropathic pain” in the platform6. It shows the ADE
caused by all drug treatments prescribed for peripheral neuro-
pathic pain in the ontology. The “Treatment summary” tab can
be used for finding the most prescribed active principles in that
indication.
Figure 14 shows the indirect comparison obtained after select-
ing the first four treatments in the “Treatment summary” tab (ex-
cluding placebo)7. There are 12 trials for pregabalin, 3 for du-
loxetine, 2 for tramadol and 1 for gabapentin. We can see that
all treatments are not equal in terms of ADE, despite the fact
that three of them were recommended as first-line treatment (pre-
gabalin, duloxetine and gabapentin). Duloxetine and tapentadol
have the highest ADE rates, with a lot of digestive ADE for both,
and of endocrine / metabolic / nutritional ADE for duloxetine, in
addition to the nervous ADE present with all four treatments.
Pregabalin and gabapentin seems better tolerated. Both be-
long to gabapentinoids, a family of antiepileptic drugs which
are also prescribed for pain. Their mechanism of action is not
fully known, but an auxiliary subunit of voltage-gated calcium
channels seems to be involved [58]. In Figure 13, gabapentin
6Available online at http://www.lesfleursdunormal.fr/appliweb/pain?
group_1_indication=peripheral neuropathic pain
7Available online at http://www.lesfleursdunormal.fr/appliweb/pain?
group_1_indication=peripheral neuropathic pain,&group_1_ap=pregabalin
&group_2_indication=peripheral neuropathic pain,&group_2_ap=duloxetine
&group_3_indication=peripheral neuropathic pain,&group_3_ap=tapentadol
&group_4_indication=peripheral neuropathic pain,&group_4_ap=gabapentin
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Figure 15: Indirect comparison of pregabalin and gabapentin. We activated the ∆
button of gabapentin, thus showing the outline of the gabapentin glyph on top of
the other one.
has the fewest ADE, but the evidence is weak because the
gabapentin group includes only 1 trial and 221 patients. Fig-
ure 15 shows a direct and indirect mixed comparison of prega-
balin vs gabapentin, including 13 trials for pregabalin and 2 for
gabapentin (one trial compare pregabalin to gabapentin with no
placebo, and was thus not present in the previous indirect com-
parison)8. The flower glyphs show that both drugs have a sim-
ilar ADE profile, but with fewer ADE for gabapentin (64.1%
vs 97.6%). This suggests that gabapentin might be preferable
in terms of safety. It also suggests that performing a compara-
tive trial between pregabalin and gabapentin, or a network meta-
analysis, may be a valuable study.
4.4. Expert opinions
The four experts were very interested by this work. They found
the proposed platform innovative and original, both in its ap-
proach and its presentation. They agreed that trial data are insuf-
ficiently exploited today by computer programs, and they found
the visual interface easy to understand and very nice.
They made several interesting suggestions. First, one expert
asked for additional statistical computations, such as relative
risks. Second, they suggested the use of the platform for ap-
proved drugs, but also before drug approval, in order to help
regulators to take the decision to approve (or not) a new drug
by comparing its adverse event profile with the other drugs al-
ready available in the same indication. Third, they also proposed
to compare the adverse event profile of a given drug in various
indications, when a drug is initially approved for an indication
and then prescribed in others. For example, it might be inter-
esting to compare the ADE of gabapentinoids when prescribed
for epilepsy and for pain: since they were initially approved for
epilepsy, their summaries of product characteristics (SPC) de-
scribe the ADE observed in epilepsy studies, but they might dif-
fer from those occurring when prescribed for pain. Finally, they
suggested using the flower glyph to visualize the adverse effects
described in SPC, and to compare them with those observed dur-
ing clinical trials.
5. Discussion
In this paper, we described how ADE mentioned in publicly
available clinical trial results could be integrated in a data mining
8Available online at http://www.lesfleursdunormal.fr/appliweb/pain?
group_1_indication=peripheral neuropathic pain&group_1_ap=pregabalin
&group_2_indication=peripheral neuropathic pain&group_2_ap=gabapentin&tab=1
platform for drug safety. This platform relies on semantic web
technologies for allowing queries at various levels of granularity,
and on visual analytics, and in particular flower glyphs, for the
presentation of the results. We illustrated the interest of this ap-
proach through case studies, and we showed that we were able to
find back results already known in the literature (e.g. regarding
elagolix, tapentadol and tramadol) but also to suggest new results
(e.g. on gabapentinoids) that would require further confirmation.
The key points of this work are the original approach producing
fact-based evidence on drug safety, by applying data science to
trial data, and the association of semantic methods with visual
analytics.
We found that there is a strong synergy between the semantic
and the visual nature of the proposed data mining platform. The
semantic nature allows searching the entire dataset in many ways,
using the links and options proposed in the various tabs. The
visual nature makes the platform ludic and enjoyable, thus giving
the user the desire to test the many possibilities offered by the
platform.
A potential problem in meta-analyses is the confirmation bias
[59], i.e. the tendency to search for, interpret and favor infor-
mation in a way that confirms the investigator hypothesis. Since
meta-analyses are performed with a hypothesis in mind, this hy-
pothesis might bias the process. On the contrary, in the present
work, the selection of clinical trials and their coding were per-
formed in a systematic manner, without aiming at answering a
specific medical question. In addition, the query procedure and
the visualization are fully automatic. As a consequence, this
might reduce the confirmation bias.
The main limitation of the proposed approach is that it highly
depends on the availability and the quality of clinical trial data.
In particular, limited data are available for older drugs. For ex-
ample, aspirin has been used for treating pain for long, but is no
longer recommended. As a consequence, there is no recent trial
involving aspirin as a painkiller, and thus we have no data in the
proposed system. Thus our platform fails to identify the risks as-
sociated with the use of aspirin as a painkiller. Similarly, we have
seen in section 4.3.4 that limited data was available for situations
of drug abuse or drug overdose.
The performances of the automatic scripts for populating the
ontology from the trial registry are not good enough to allow a
fully automatic process. Consequently, an automatic update of
the ontology is not possible. Most sophisticated Natural Lan-
guage Processing (NLP) methods, e.g. Recurrent Neural Net-
work (RNN) [60], might achieve better performances. These
machine learning methods require a manually labeled training
dataset, which was not available in our case. However, the ontol-
ogy populated here could now be used as a training set, and, in
future work, we plan to experiment RNN based NLP techniques.
The model we proposed for structuring trials matches the
needs of pain treatments, but remains very limited. A more com-
plex model would be required for generalizing the platform be-
yond pain treatment, e.g. a model able to represent chemotherapy
regimen or time of drug intake.
In the literature, the closest use of flower glyphs is the work
of Pilato et al. for the analysis of social sensing on Twitter [42].
The authors proposed flower glyphs with 7 colored petals and a
center part, corresponding to various emotions (joy, fear,...). In
the present work, we extended flower glyphs for the visualiza-
tion of all vs serious ADE, using an inner, darker, petal. Color
blind people may not be able to distinguish the various colors of
flower glyphs. However, the information carried by the color is
redundant with the information carried by the orientation of the
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petal, thus color blind people should still be able to use flower
glyphs efficiently. Most colors on the flower glyph are culturally
independent (e.g. red for blood). A notable exception is the color
of the “skin and subcutaneous tissue” category.
The proposed platform is limited to descriptive and visual anal-
ysis, but does not perform statistical tests, e.g. in order to test
whether a difference observed in ADE rate is significant or not.
While theoretically feasible, implementing statistical tests raises
a problem: each test is associated with a risk α (usually 5%) and
a risk β, and multiplying the test cumulates these risks. It is com-
monly accepted that, above 5-10 tests, a correction is necessary.
Therefore, we decided not to propose statistical tests for now. For
indirect comparison, we used placebo as a reference. This works
well for mild to moderate pain, however, for severe pain such
as cancer pain, placebo may not be a valid option from an ethical
point of view. In this case, other references should be considered,
e.g. morphine.
6. Conclusion
In conclusion, we proposed a method and a platform for the
analysis of adverse events observed during clinical trials, and
published in trial registries. We applied the platform to pain
treatment, and we showed that we were able to obtain results
already known from meta-analyses, but also to suggest new in-
sights. These results interested drug safety experts.
This work opens many perspectives for future research. First,
the automatization of the ontology population from trial registries
could be improved, e.g. using deep learning and text mining for
extracting drug treatments and their indication. Second, the pro-
posed system could be extended to the visualization of patient
outcomes in trials, in order to evaluate drug treatment efficacy,
or to other data sources, such as ADE declared in pharmacovigi-
lance databases, or ADE observed in real-world prescription data
such as health records and OHDSI (Observational Health Data
Sciences and Informatics). Third, flower glyphs could be adapted
to the presentation of the rate of potential adverse effects de-
scribed in drug summaries of product characteristics (SPC) or
patient leaflets. Fourth, the proposed approach could be applied
to other medical domains beyond pain treatment. Finally, the use
of the proposed web platform could be experimented in medi-
cal initial and continuing education, or associated with decision
support tools for prescriptions.
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